Table 1 Cost parameters (in 2012 Canadian dollar per patient)
Source of costs | Mean | SD | RSD | Distribution | Hyperparameters | Sourcea |
|---|---|---|---|---|---|---|
Pre-transplant visit | 569 | University of Alberta Hospital | ||||
Transplantation (including initial medication, based on 4 day stay: 1 pre-op and 3 post-op) | 91,414 | 15.0 % | Log-Normal | μ = 11.412029 | University of Alberta Hospital | |
σ = 0.149166 | ||||||
Total costs per transplantation (including all costs in the 23 days after a transplantation) | 94,765 | (via input) | ||||
Medication and follow-up (from day 4 post-op onward) | ||||||
Tacrolimus (per month) | 450 | 7.5 % | Log-Normal | μ = 6.106443 | University of Alberta Hospital | |
σ = 0.074895 | ||||||
Mycophenolate mofetil (MMF; per month) | 500 | 7.5 % | Log-Normal | μ = 6.211803 | University of Alberta Hospital | |
σ = 0.074895 | ||||||
Alemtuzumab (once per transplant)b | 0 | University of Alberta Hospital | ||||
Basiliximab (once at 2nd transplant for about half of patients instead of Alemtuzumab) | 3000 | University of Alberta Hospital | ||||
Valganciclovir (for 14 weeks) | 5000 | 375 | 7.5 % | Log-Normal | μ = 8.514389 | University of Alberta Hospital |
σ = 0.074895 | ||||||
Anakinra (total for remaining 3 days after discharge) | 574 | 43 | 7.5 % | Log-Normal | μ = 6.349825 | University of Alberta Hospital |
σ = 0.074895 | ||||||
Immunosuppression (per cycle, drugs: see above) | 713 | 53 | 7.5 % | Log-Normal | μ = 6.56667 | Calculated via data from University of Alberta Hospital |
σ = 0.074895 | ||||||
Generic immunosuppression (per cycle) | 238 | 18 | 7.5 % | Log-Normal | μ =5.46808 | Calculated as 1/3 of cost above (price reduction for generic version based on market prices) |
σ = 0.074895 | ||||||
Costs for insulin therapy in graft survival state (per cycle) | 64 | (via input) | Calculated via data from [33] and based on [10] as 40 % of costs with intensive insulin therapy | |||
Post-transplant check-up visit (at week 1, 2, at 6 months and 1 year and then once a year) | 556 | 42 | 7.5 % | Log-Normal | μ = 6.31800 | University of Alberta Hospital |
σ = 0.074895 | ||||||
Total per cycle (per year) costs for immunosuppression, follow-up and insulin (if applicable) | ||||||
Full graft function for the first 6 months | 1886 (30,175) | (via inputs) | Calculated via data from University of Alberta Hospital | |||
Full graft function after the first 6 months | 747 (11,956) | (via inputs) | Calculated via data from University of Alberta Hospital | |||
Partial graft function for the first 6 months | 1950 (31,196) | (via inputs) | Calculated via University of Alberta Hospital data and [33] | |||
Partial graft function after the first 6 months | 811 (12,977) | (via inputs) | Calculated via University of Alberta Hospital data and [33] | |||
Intensive insulin therapy | ||||||
Average healthcare costs of treating people with newly diagnosed diabetes (first 10 years) per cycle (per year) | ||||||
Without complications for type 1 and 2 diabetes | 159 (2552) | 12 | 7.5 % | Log-Normal | μ = 5.06920 | Corrected data from [33] |
σ = 0.074895 | ||||||
With complications for type 1 and 2 diabetes | 602 (9632) | 120 | 20.0 % | Gamma | α = 25.00000 | Calculated from corrected data in [33] |
β = 24.0796 | ||||||
Other costs (per occurrence) | ||||||
Average extra costs of initial immunosuppressive or other complications | 600 | 180 | 30.0 % | Gamma | α = 11.1111 | Assumption based on [2] and expert opinion |
β = 54.0000 | ||||||
Average extra costs of major immunosuppressive complications | 6500 | 1300 | 20.0 % | Gamma | α = 25.0000 | Assumption based on [2] and expert opinion |
β = 260.0000 | ||||||